Oncology
Plasma Cell Leukemia
26
Pipeline Programs↗
12
Active Trials↗
9
Companies Involved↗
Plasma Cell Leukemia is an emerging landscape with 26 programs across 9 companies. The most active players are Nanjing IASO Biotechnology Co., Ltd., Bayer, Gynecologic Oncology Group. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 19
Phase 215
Phase 3
No programs
Approved1
Analysis
Modality Breakdown
27programs
Small molecule1659%
Cell therapy726%
Monoclonal antibody311%
Protein / enzyme14%
Modality classified for 100% of 30 pipeline programs.
Analysis
Trial Status
19
clinical trials
Recruiting8 · 42%
Completed4 · 21%
Not yet recruiting3 · 16%
Unknown status2 · 11%
Withdrawn1 · 5%
Active, not recruiting1 · 5%
Clinical Trials
Trial Activity
19 trials
A Study of CT0596 in Plasma Cell Leukemia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06988059·27 enrolled
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Recruiting·—·Phase 1·NCT05219721·18 enrolled
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07106684·20 enrolled
A Prospective, Single-center, Phase II Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Newly Diagosed Primary Plasma Cell Leukemia
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05870917·20 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)